NCT07080931

Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study on the Efficacy and Safety of 5% Minoxidil Foam in the Treatment of Female Androgenetic Alopecia

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 294 (estimated)
• Sponsor: Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate the efficacy of once-daily 5% minoxidil foam versus placebo in female androgenetic alopecia, using the Target Area Terminal Hair Count (TAHC) as the primary endpoint.

Conditions

• Androgenetic Alopecia

Interventions

Type	Name	Description
DRUG	5% minoxidil foam	Trial participants applied 5% minoxidil foam topically once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.
DRUG	Placebo for 5% Minoxidil Foam	Trial participants applied placebo once daily (QD) in the morning or evening, with a maximum daily dose not exceeding 1 g, for up to 24 weeks.

Timeline

• Start date: 2025-02-24
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-07-23
• Last updated: 2026-03-05

Locations

1 site across 1 country: China